Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions

Scott R. Penzak, Kristin H. Busse, Sarah M. Robertson, Elizabeth Formentini, Raul M. Alfaro, Richard T. Davey

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Midazolam is a common probe used to predict CYP3A activity, but multiple blood samples are necessary to determine midazolam's area under the concentration-time curve (AUC). As such, single sampling strategies have been examined. The purpose of this study was to assess the ability of single midazolam concentrations to predict midazolam AUC in the presence and absence of CYP3A modulation by Ginkgo biloba extract (GBE). Subjects received oral midazolam 8 mg before and after 28 days of GBE administration. Postdose blood samples were collected during both study periods and midazolam AUC determined. Linear regression was used to generate measures of predictive performance for each midazolam concentration. The geometric mean ratio (90% confidence intervals) of midazolam AUC0-∞ postGBE/AUC 0-∞ pre-GBE was 0.66 (0.49-0.84) (P =.03). Before and after GBE administration, optimal midazolam sampling times were identified at 3.5 to 5 hours and 2 to 3 hours, respectively. Single midazolam concentrations between 2 and 5 hours correctly predicted the reduction in midazolam AUC following GBE exposure, but confidence intervals were generally wide. Intersubject variability in CYP3A activity (either inherent or from drug administration) alters the prediction of optimal midazolam sampling times; therefore, midazolam AUC is preferred for assessing CYP3A activity in drug-drug interaction studies.

Original languageEnglish
Pages (from-to)671-680
Number of pages10
JournalJournal of Clinical Pharmacology
Volume48
Issue number6
DOIs
StatePublished - Jun 2008

Keywords

  • CYP3A
  • Drug interactions
  • Ginkgo biloba extract
  • Midazolam

Fingerprint Dive into the research topics of 'Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions'. Together they form a unique fingerprint.

  • Cite this

    Penzak, S. R., Busse, K. H., Robertson, S. M., Formentini, E., Alfaro, R. M., & Davey, R. T. (2008). Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions. Journal of Clinical Pharmacology, 48(6), 671-680. https://doi.org/10.1177/0091270008317305